ODTX (Odyssey Therapeutics) Other Current Liabilities: $2.75 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ODTX Odyssey Therapeutics Inc ODTX
7 GF Score
Price $18.92
! 3 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Other Current Liabilities?

Odyssey Therapeutics ODTX +3.16% 7 Other Current Liabilities is $2.75 Mil as of Mar. 2026. GuruFocus rates ODTX with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

Odyssey Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $2.75 Mil.

Odyssey Therapeutics's quarterly other current liabilities increased from Mar. 2025 ($0.00 Mil) to Dec. 2025 ($7.08 Mil) but then declined from Dec. 2025 ($7.08 Mil) to Mar. 2026 ($2.75 Mil).

Odyssey Therapeutics's annual other current liabilities declined from Dec. 2023 ($7.47 Mil) to Dec. 2024 ($6.93 Mil) but then increased from Dec. 2024 ($6.93 Mil) to Dec. 2025 ($7.08 Mil).

Odyssey Therapeutics Other Current Liabilities Related Terms

Odyssey Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Other Current Liabilities Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
6.45 7.47 6.93 7.08

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial 4.80 6.93 0.00 7.08 2.75
ODTX
7GF Score
Odyssey Therapeutics Inc ODTX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $2.75 Mil mean?
Odyssey Therapeutics (ODTX) has a Other Current Liabilities of $2.75 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Odyssey Therapeutics.
Is Odyssey Therapeutics' Other Current Liabilities too high?
Odyssey Therapeutics' current Other Current Liabilities is $2.75 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Other Current Liabilities compare to SANA and GERN?
Odyssey Therapeutics' Other Current Liabilities of $2.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Odyssey Therapeutics. Odyssey Therapeutics's current Other Current Liabilities is $2.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Other Current Liabilities of $2.75 Mil. The current Other Current Liabilities is $2.75 Mil. Odyssey Therapeutics' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Other Current Liabilities is $2.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
7GF Score

Get the complete analysis for ODTX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.92
Price